To speak to the international piece and the FDA, the Food and Drug Administration is taking similar steps to what we are proposing. They are moving collaboratively with industry, as we are as well, to remove growth promotion claims from medically important antimicrobials so that such use does not occur.
The second thing is increasing the veterinary oversight over medically important antimicrobials. They are taking the same approach: that a veterinarian should be involved prior to purchase of a medically important antimicrobial. They have different tools at their disposal, but the veterinary oversight is exactly what they are proposing and in fact doing.